Clinical Trial

A Phase 1 Study of ADI-001 in Rheumatoid Arthritis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
ADI-001-106 is a phase 1 study of ADI-001 with a randomized, single-blind, parallel group design to compare two different LD regimens in subjects with treatment-refractory RA. The study will consist of different periods including screening, LD, treatment, and follow-up
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-28.
Status change: Not Yet Recruiting → Recruiting 2025-12-01
Trial Details
NCT Number NCT07100873
Lead Sponsor Adicet Therapeutics
Conditions Rheumatoid Arthritis (RA)
Enrollment 25 participants
Start Date 2025-10-10
Primary Completion 2027-03-30 (estimated)
Study Completion 2028-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-08